CoChat

Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials

Open access
Liu, Dangzhen, Zhao, Haiyan, Zhang, Yiwen, Hu, Jingqing, Xu, Hong · 2025 · Frontiers in Pharmacology

The DOI matches its Crossref record; 57 of the 59 references it cites were found in a registry or an index; 7 of the 21 sources its claims cite were checked for support.

Abstract

Background Metabolic syndrome (MetS) is a prevalent metabolic disease that significantly increases the risk of type 2 diabetes, cardiovascular diseases, and overall mortality. Current medications have limited effects on the various components of MetS. Berberine has demonstrated unique comprehensive therapeutic benefits for MetS, but its efficacy remains uncertain. Objective To comprehensively evaluate the efficacy and safety of berberine on MetS indicators. Methods Our study provides a comprehensive evaluation of the efficacy and safety of berberine for MetS components through systematic review and meta-analysis, from the aspects of study characteristics, risk of bias, meta-analysis, sensitivity analysis, meta-regression, and publication bias. Results The results indicate that berberine significantly reduces triglycerides (TG) (WMD: −0.367 mmol/L; 95% CI: −0.560 to −0.175; p < 0.001), fasting plasma glucose (FPG) (WMD: −0.515 mmol/L; 95% CI: −0.847 to −0.183; p = 0.002), and waist circumference (WC) (WMD: −3.270 cm; 95% CI: −4.818 to −1.722; p < 0.001) among the components of MetS, but has no significant effect on high-density lipoprotein cholesterol (HDL-C), systolic blood pressure (SBP), or diastolic blood pressure (DBP). Additionally, berberine also improves the secondary indicators of low-density lipoprotein cholesterol (LDL-C) (WMD: −0.495 mmol/L; 95% CI: −0.714 to −0.276; p < 0.001), total cholesterol (TC) (WMD: −0.451 mmol/L; 95% CI: −0.631 to −0.271; p < 0.001), body mass index (BMI) (WMD: −0.435 kg/m 2 ; 95% CI: −0.856 to −0.013; p = 0.043), and 2-h oral glucose tolerance (2hOGTT) (WMD: −1.606 mmol/L; 95% CI: −1.891 to −1.321; p < 0.001). Meta-regression and subgroup analyses indicate that short-term treatment (≤90 days) is more effective for HDL-C and LDL-C than long-term treatment. Regarding safety, no significant difference was observed between berberine and placebo. Conclusion Berberine significantly improves glucose and lipid metabolism and has notable effects on components of MetS, including TG, FPG, and WC, with a favorable safety profile. It may serve as a beneficial supplement. Meanwhile, more high-quality, rigorously designed randomized controlled trials are needed in the future to provide stronger evidence. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD42024588614 .

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis of 12 randomized placebo-controlled trials (889 participants) found berberine significantly reduced TG, FPG, WC, and secondary LDL-C, TC, BMI, and 2hOGTT, but not HDL-C, SBP, or DBP, with no significant safety difference versus placebo. Short-term treatment (≤90 days) was more effective for HDL-C and LDL-C than longer treatment.

Key findings

  • Berberine significantly reduced TG (WMD: −0.367 mmol/L; 95% CI: −0.560 to −0.175; p < 0.001; I² = 81.2%), FPG (WMD: −0.515 mmol/L; 95% CI: −0.847 to −0.183; p = 0.002; I² = 89.8%), and WC (WMD: −3.270 cm; 95% CI: −4.818 to −1.722; p < 0.001; I² = 0.00%).
  • No significant effect was found on HDL-C (WMD: 0.016 mmol/L; 95% CI: −0.045 to 0.078; p = 0.60), SBP (WMD: −0.879 mmHg; 95% CI: −7.223 to 5.464; p = 0.786), or DBP (WMD: 0.424 mmHg; 95% CI: −4.894 to 5.741; p = 0.876).
  • Secondary outcomes improved: LDL-C (WMD: −0.495 mmol/L; 95% CI: −0.714 to −0.276; p < 0.001), TC (WMD: −0.451 mmol/L; 95% CI: −0.631 to −0.271; p < 0.001), BMI (WMD: −0.435 kg/m²; 95% CI: −0.856 to −0.013; p = 0.043), and 2hOGTT (WMD: −1.606 mmol/L; 95% CI: −1.891 to −1.321; p < 0.001).
  • Safety showed no significant difference versus placebo: pooled RR for any adverse event 1.07 (95% CI: 0.15–6.76; p = 0.746), any gastrointestinal adverse event 1.44 (95% CI: 0.85–2.42; p = 0.172), and stool abnormalities 1.52 (95% CI: 0.67–3.44; p = 0.314). Short-term treatment (≤90 days) was more effective for HDL-C and LDL-C than long-term treatment.

Methods

  • Systematic review and meta-analysis of randomized placebo-controlled trials comparing purified berberine versus placebo; databases searched were PubMed, Web of Science, Embase, Cochrane Library, and China National Knowledge Infrastructure from inception to 15 November 2024, with no language restrictions; PROSPERO registration CRD42024588614.
  • Twelve parallel placebo-controlled RCTs published between 2004 and 2023 were included, totaling 889 participants; populations included dyslipidemia, T2DM-associated dyslipidemia, hyperglycemia, drug-induced impaired fasting glucose, prediabetes, PCOS with infertility, high HDL-C syndrome, metabolic syndrome, and HIV-infected individuals with metabolic syndrome; berberine dosages ranged from 300 to 1,500 mg/day and intervention durations from 84 to 140 days.
  • Analyses used STATA 17.0 (safety in Python 3.12), reporting weighted mean differences with 95% CIs; random-effects models were used when I² > 50% and fixed-effects models when I² ≤ 50%; subgroup analyses, meta-regression, sensitivity analysis, and publication-bias assessment (funnel plots, Egger’s test, Begg-Mazumdar test, trim-and-fill) were performed; risk of bias was assessed with Cochrane RoB 2.

Limitations

  • The paper states substantial heterogeneity remained for TG, HDL-C, LDL-C, and FPG despite subgroup and meta-regression analyses; included studies had methodological shortcomings; populations varied; subgroup analyses for WC, SBP, DBP, and 2hOGTT could not be performed due to limited study numbers; safety data were incomplete in several studies and two of 12 included studies lacked safety data; current evidence is insufficient to claim syndrome-level remission.
  • The paper states two low-quality studies (Pu et al., 2021; Ran, 2023) were excluded in an additional meta-analysis; after exclusion, BMI effect attenuated (WMD: −0.302 kg/m²; 95% CI: −0.736 to 0.132; p = 0.173).
  • Evident from the text: publication bias was detected for TG by Egger’s test (p = 0.041) and Begg’s test (p = 0.048), though trim-and-fill left the TG result unchanged; 2hOGTT sensitivity analysis was influenced by Panigrahi and Mohanty (2023); one included study was open-label.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fphar.2025.1572197

Cites

57 of 58 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 PRISMA flow diagram of selecting studies.
FIGURE 1 PRISMA flow diagram of selecting studies.CC BY · PubMed Central
FIGURE 2 Summary plot of Cochrane Collabration’s risk of bias tool 2 of (A) Risk of bias summary and (B) Risk of bias diagram.
FIGURE 2 Summary plot of Cochrane Collabration’s risk of bias tool 2 of (A) Risk of bias summary and (B) Risk of bias diagram.CC BY · PubMed Central
FIGURE 3 Forest plot reporting WMD and 95% CI for the efforts of berberine intake on (A) TG (B) HDL-C; (C) LDL-C (D) BMI; (E) TC (F) FPG; (G) WC (H) SBP; (I) DBP; (J) 2h-OGTT.
FIGURE 3 Forest plot reporting WMD and 95% CI for the efforts of berberine intake on (A) TG (B) HDL-C; (C) LDL-C (D) BMI; (E) TC (F) FPG; (G) WC (H) SBP; (I) DBP; (J) 2h-OGTT.CC BY · PubMed Central
FIGURE 4 Sensitivity analysis was performed by removing each study in turn to determine the impact of each study on the overall effect size. (A) TG; (B) HDL-C (C) LDL-C; (D) BMI (E) TC; (F) FPG (G) WC; (H) SBP (I) DBP; (J) 2h-OGTT.
FIGURE 4 Sensitivity analysis was performed by removing each study in turn to determine the impact of each study on the overall effect size. (A) TG; (B) HDL-C (C) LDL-C; (D) BMI (E) TC; (F) FPG (G) WC; (H) SBP (I) DBP; (J) 2h-OGTT.CC BY · PubMed Central
FIGURE 5 Meta-regression analysis between berberine dosage and mean difference (A) TG (B) HDL-C; (C) LDL-C (D) BMI; (E) TC; (F) FPG. 1 ≤ 0.9 g/day, 2 = 1 g/ gay, 3 ≥ 1.5 g/day. The size of the bubble represents the weight of each individual study.
FIGURE 5 Meta-regression analysis between berberine dosage and mean difference (A) TG (B) HDL-C; (C) LDL-C (D) BMI; (E) TC; (F) FPG. 1 ≤ 0.9 g/day, 2 = 1 g/ gay, 3 ≥ 1.5 g/day. The size of the bubble represents the weight of each individual study.CC BY · PubMed Central
FIGURE 6 Meta-regression analysis between berberine duration and mean difference (A) TG (B) HDL-C; (C) LDL-C (D) BMI; (E) TC; (F) FPG. 1 = day, 2 = 90 days, 3 ≥ 112 days. The size of the bubble represents the weight of each individual study.
FIGURE 6 Meta-regression analysis between berberine duration and mean difference (A) TG (B) HDL-C; (C) LDL-C (D) BMI; (E) TC; (F) FPG. 1 = day, 2 = 90 days, 3 ≥ 112 days. The size of the bubble represents the weight of each individual study.CC BY · PubMed Central
FIGURE 7 Meta-regression analysis between berberine gender and mean difference (A) TG (B) HDL-C; (C) LDL-C (D) BMI; (E) TC; (F) FPG. 1 = male predominant, 2 = female-predominant. The size of the bubble represents the weight of each individual study.
FIGURE 7 Meta-regression analysis between berberine gender and mean difference (A) TG (B) HDL-C; (C) LDL-C (D) BMI; (E) TC; (F) FPG. 1 = male predominant, 2 = female-predominant. The size of the bubble represents the weight of each individual study.CC BY · PubMed Central
FIGURE 8 Meta-regression analysis between berberine gender and mean difference (A) TG (B) HDL-C; (C) LDL-C (D) BMI; (E) TC; (F) FPG. 1 = 20-39 years, 2 = 40-59 years female-predominant. The size of the bubble represents the weight of each individual study.
FIGURE 8 Meta-regression analysis between berberine gender and mean difference (A) TG (B) HDL-C; (C) LDL-C (D) BMI; (E) TC; (F) FPG. 1 = 20-39 years, 2 = 40-59 years female-predominant. The size of the bubble represents the weight of each individual study.CC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 1 Not valid · 7 Not checked · 118 Own results and interpretations

81 more claims

Create a free account to see all 132 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 14
  • It may state two separate claims as one. 36
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 8 · the rest aren’t loaded

3 more findings

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 58 references

Research works printed but not linked: 1

  1. Ran, 2023, Clinical study of berberine in the treatment of low HDL-C.

Cited by

See all 24

Metadata

Authors
Liu, D., Zhao, H., Zhang, Y., Hu, J., & Xu, H.
Affiliations
  • Chengdu University of Traditional Chinese Medicine (CN)
  • Nanjing University of Chinese Medicine (CN)
  • Institute of Basic Theory for Chinese Medicine (CN)
  • Guangzhou University of Chinese Medicine (CN)
Corresponding author
Hu, Jingqing
Venue
Frontiers in Pharmacology
Published
2025-07-16
Volume
16
Pages
1572197-1572197
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4412465953
Cited by
24
References
59
Citations by year
2026: 21 · 2025: 3
FWCI
3.26
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
China Academy of Traditional Chinese Medicine
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
Keywords
berberine, metabolic syndrome, triglycerides, fasting blood glucose, waist circumference, LDL cholesterol, total cholesterol, blood pressure, body mass index, oral glucose tolerance, insulin resistance, type 2 diabetes prevention, drug safety, adverse events, hepatotoxicity, gastrointestinal adverse effects, drug interactions, herbal medicine, antidiabetic drugs, lipid metabolism, antihypertensive drugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. https://app.cochat.ai/papers/10.3389/fphar.2025.1572197
The paper
Liu, D., Zhao, H., Zhang, Y., Hu, J., & Xu, H. (2025). Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2025.1572197

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.